AIDA Oncology develop OncoTect® predictors that use RNA expression from a single biopsy to predict how a patient’s tumour will respond to chemotherapy. Starting with breast cancer, they aim to help clinicians choose the most effective treatment from the start and spare patients from treatments that won’t work.